News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
4,173 Results
Type
Article (1058)
Company Profile (4)
Press Release (3111)
Section
Business (1285)
Career Advice (58)
Deals (172)
Drug Delivery (6)
Drug Development (1174)
Employer Resources (11)
FDA (210)
Job Trends (459)
News (2585)
Policy (392)
Tag
2024 Biotech Bay Standard (1)
2026 Biotech Bay Standard (1)
Academia (28)
Accelerated approval (1)
Allergies (4)
Alliances (277)
Alzheimer's disease (6)
Antibody-drug conjugate (ADC) (2)
Approvals (208)
Artificial intelligence (1)
Autoimmune disease (1)
Bankruptcy (2)
Best Places to Work (392)
Biosimilars (11)
Biotechnology (3)
Breast cancer (2)
Cancer (31)
Cardiovascular disease (3)
Career advice (45)
Career pathing (1)
CAR-T (2)
Cell therapy (12)
Clinical research (853)
Collaboration (10)
Complete response letters (3)
COVID-19 (185)
CRISPR (4)
C-suite (3)
Data (35)
Denatured (3)
Diabetes (1)
Diagnostics (32)
Digital health (1)
Diversity (3)
Diversity, equity & inclusion (3)
Drug discovery (2)
Drug pricing (4)
Duchenne muscular dystrophy (2)
Earnings (570)
Editorial (1)
Employer branding (7)
Employer resources (10)
Events (579)
Executive appointments (3)
FDA (225)
Featured Employer (2)
Funding (9)
Gene editing (8)
Gene therapy (17)
GLP-1 (30)
Government (115)
Grass and pollen (1)
Guidances (1)
Healthcare (123)
Immunology and inflammation (11)
Infectious disease (187)
Influenza (1)
Interviews (11)
IPO (105)
IRA (1)
Job creations (87)
Job search strategy (45)
Labor market (2)
Layoffs (19)
Legal (53)
Liver cancer (2)
Lung cancer (5)
Lymphoma (4)
Management (2)
Manufacturing (3)
Medical device (20)
Medtech (20)
Mergers & acquisitions (71)
Metabolic disorders (19)
Multiple sclerosis (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (1)
Neuroscience (10)
NextGen: Class of 2025 (58)
Non-profit (15)
Northern California (25)
Now hiring (15)
Obesity (17)
Opinion (4)
Pain (2)
Patents (5)
Peanut (1)
People (373)
Pharmaceutical (1)
Phase I (265)
Phase II (340)
Phase III (484)
Pipeline (29)
Podcasts (9)
Policy (2)
Postmarket research (19)
Preclinical (71)
Rare diseases (6)
Real estate (32)
Recruiting (3)
Regulatory (294)
Reports (2)
Research institute (17)
Resumes & cover letters (6)
RSV (1)
Series A (5)
Series B (2)
Southern California (5)
Special edition (2)
Spinal muscular atrophy (1)
Startups (13)
Tariffs (2)
The Weekly (6)
United States (190)
Vaccines (21)
Venture capitalists (3)
Webinars (1)
Weight loss (15)
Women's health (2)
Date
Today (1)
Last 7 days (5)
Last 30 days (23)
Last 365 days (395)
2025 (113)
2024 (387)
2023 (354)
2022 (557)
2021 (555)
2020 (535)
2019 (333)
2018 (237)
2017 (237)
2016 (167)
2015 (154)
2014 (105)
2013 (108)
2012 (81)
2011 (59)
2010 (45)
Location
Africa (23)
Asia (161)
Australia (58)
California (39)
Canada (4)
China (1)
Connecticut (4)
Delaware (2)
Europe (800)
Idaho (1)
Illinois (5)
Indiana (1)
Iowa (1)
Japan (1)
Maryland (1)
Massachusetts (39)
Michigan (1)
Minnesota (1)
Nebraska (1)
New Hampshire (2)
New Jersey (4)
New York (96)
North Carolina (5)
Northern California (25)
Ohio (2)
Oregon (1)
Pennsylvania (5)
Rhode Island (1)
South America (23)
Southern California (5)
Texas (1)
Virginia (1)
Washington D.C. (2)
Washington State (4)
Wisconsin (1)
4,173 Results for "regeneron".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
Regeneron Loses Appeal to Block Amgen’s Eylea Biosimilar
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea.
March 17, 2025
·
2 min read
·
Tristan Manalac
Legal
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that determine pricing and rebates for the drug.
February 7, 2025
·
2 min read
·
Tristan Manalac
Earnings
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall thanks in part to cancer therapy Libtayo and gave shareholders a cut of the profits for the first time in the company’s long history.
February 4, 2025
·
2 min read
·
Tristan Manalac
Drug development
Opthea, UNITY Fail to Unseat Regeneron’s Eylea in Vision Disorders
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s biosimilar from the U.S.
March 25, 2025
·
2 min read
·
Tristan Manalac
Cancer
Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo
The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which exceeded the consensus by a modest 1% and are bogged down by the slow conversion of patients to the high-dose formulation.
January 14, 2025
·
2 min read
·
Tristan Manalac
Postmarket research
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts
The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment.
December 17, 2024
·
2 min read
·
Tristan Manalac
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
September 27, 2024
·
2 min read
·
Kate Goodwin
Gene therapy
Regeneron’s Gene Therapy Restores Hearing in Patients with Rare Genetic Condition
The treatment, called DB-OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic deafness.
February 24, 2025
·
4 min read
·
Dan Samorodnitsky
Earnings
Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously optimistic about the company’s promising cancer, immunology and genetic medicines pipeline.
November 1, 2024
·
2 min read
·
Tristan Manalac
Legal
Amgen Gets Legal Win in Eylea Patent Row With Regeneron
Regeneron’s lawsuit, filed earlier this year, alleged more than 30 counts of patent infringement against Amgen and its biosimilar to the blockbuster eye therapy Eylea.
September 24, 2024
·
2 min read
·
Tristan Manalac
1 of 418
Next
